查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492224

骨转移市场：按治疗类型、类型、最终用户、适应症分类 - 全球预测 2024-2030

Bone Metastasis Market by Treatment Type (Medications, Therapy), Type (Mixed Bone Metastasis, Osteoblastic Bone Metastasis, Osteolytic Bone Metastasis), End-User, Indication - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年骨转移市场规模为182.4亿美元，预计2024年将达196.2亿美元，2030年将达306.6亿美元，复合年增长率为7.69%。

当癌细胞从原来的部位扩散到骨骼时，就会发生骨转移。与从骨骼开始的原发性骨癌不同​​，骨转移意味着癌症从身体的其他部位开始，然后转移到骨骼。许多不同类型的癌症都可能发生这种情况，包括乳癌、摄护腺癌和肺癌。当癌细胞侵入骨骼时，它们会破坏骨骼的正常健康和强度，通常会导致疼痛、骨折和其他严重的骨骼问题。转移性癌细胞会造成正常骨组织分解和再生过程的不平衡，进而削弱骨骼。全球癌症发病率的快速上升、多项癌症意识项目的激增以及全球人口老化正在推动市场成长。然而，骨转移治疗的商业化和产品标准化有限以及骨转移治疗产品开拓的复杂性可能会阻碍市场成长。然而，诊断成像技术的进步以及人工智慧和机器学习在治疗个人化和预测分析中的引入可能会为骨转移市场创造成长机会。

主要市场统计
基准年[2023] 182.4亿美元
预测年份 [2024] 196.2亿美元
预测年份 [2030] 306.6亿美元
复合年增长率（%） 7.69%

区域洞察

在美洲，尤其是美国和加拿大，乳癌和摄护腺癌等容易转移到骨骼的癌症盛行率很高。这增加了对先进治疗方法和诊断的需求。这些地区的患者和医疗保健提供者重视用于早期检测的综合护理以及创新成像和分子诊断技术。在美洲，临床试验正在进行中，主要重点是降低与骨转移相关的发生率，并且正在投入大量投资来研究新的治疗方法。欧洲国家为不同的患者群体提供服务，由于不同的遗传背景和医疗基础设施，他们需要个人化的治疗选择。欧盟国家受益于全民健康保险，该保险通常涵盖癌症治疗，包括骨转移的高级治疗。患者可以获得相对容易获得的医疗保健服务，包括新药物和技术。根据「欧洲地平线」计画并在欧盟委员会的资助下，多项研究合作旨在加强整个欧盟的癌症诊断和治疗。在中东和非洲地区，虽然海湾国家保持着高标准的医疗保健，但非洲国家往往资源有限，医疗设施和可及性水准参差不齐。世界各地的非政府组织也正在采取一系列倡议来加强非洲的癌症治疗。亚太地区的人口正在老化，特别是在日本和中国，由于癌症意识的增强和医疗基础设施的改善，印度等国家的癌症发生率正在上升。亚太地区对具有成本效益的治疗的需求正在增加。各国正致力于生产昂贵药物的学名药，以使治疗更容易取得。

FPNV定位矩阵

FPNV 定位矩阵对于评估骨转移市场供应商的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对骨转移市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争力的宝贵见解，包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在骨转移市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于癌症发生率上升，对产品的需求增加
      • 扩大临床环境中的效用与应用
    • 抑制因素
      • 治疗费用上涨和报销政策有限
    • 机会
      • 开发先进的治疗方法和创新药物
      • 扩大製药公司与研究机构之间的策略联盟
    • 任务
      • 假药的存在
  • 市场区隔分析
    • 类型：乳癌、肺癌和多发性骨髓瘤病例中出现溶骨性骨转移的快速趋势
    • 适应症：前列腺癌骨转移的趋势增加
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章依治疗类型分類的骨转移市场

  • 药品
  • 治疗

第七章骨转移市场：依类型

  • 混合性骨转移
  • 成骨细胞骨转移
  • 溶骨性骨转移

第 8 章骨转移市场：依最终用户分类

  • 医院/诊所
  • 研究机构。
  • 专业癌症治疗中心

第九章骨转移市场（按适应症）

  • 乳癌
  • 肺癌
  • 摄护腺癌

第十章北美和南美骨转移市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太骨转移市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲骨转移市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准Denosumab生物相似药，扩大骨相关疾病的治疗选择
    • FDA核准Medtronic增强 OsteoCool 2.0 系统用于骨肿瘤消融
    • Telix Pharmaceuticals Limited 的策略性收购利用 QSAM Biosciences, Inc. 的创新放射性药物平台来增强骨癌的治疗选择
  • 战略分析和建议

第14章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-5D693B46C017

[182 Pages Report] The Bone Metastasis Market size was estimated at USD 18.24 billion in 2023 and expected to reach USD 19.62 billion in 2024, at a CAGR 7.69% to reach USD 30.66 billion by 2030.

Bone metastasis arises when cancer cells spread from their original site to the bone. Unlike primary bone cancer, which begins in the bones, bone metastasis means the cancer originated elsewhere in the body and then traveled to the bone. This can occur in various types of cancer, including breast, prostate, and lung cancers. When cancer cells invade the bone, they can interfere with the usual health and strength of the bone, often leading to pain, fractures, and severe other bone problems. The metastatic cancer cells can create an imbalance in the normal bone tissue breakdown and regeneration process, weakening bones. Burgeoning incidences of cancer globally, the surge in several cancer awareness programs, and global population aging drive the market growth. However, limited commercialization and product standardization in bone metastasis treatments and complexities in product development for bone metastasis treatments can deter market growth. Nevertheless, advancements in diagnostic imaging technologies and the incorporation of AI and machine learning in treatment personalization and predictive analytics create potential opportunities for bone metastasis market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 18.24 billion
Estimated Year [2024] USD 19.62 billion
Forecast Year [2030] USD 30.66 billion
CAGR (%) 7.69%

Regional Insights

In the Americas, particularly in the United States and Canada, there is a high prevalence of cancers such as breast and prostate, which are prone to metastasize to bones. This escalates the demand for advanced therapies and diagnostics. Patients and healthcare providers in these regions emphasize integrated care and innovative imaging and molecular diagnostics technologies for early detection. The Americas sees significant investment in research on novel treatments, with ongoing clinical trials primarily focused on reducing the morbidity associated with bone metastases. European countries deal with a diverse patient demographic needing personalized treatment options due to varied genetic backgrounds and healthcare infrastructures. EU countries benefit from universal healthcare systems, which generally cover cancer care, including advanced treatments for bone metastasis. Patients have relatively more accessible healthcare services, including new drugs and technologies. Multiple EU-wide collaborations aim to enhance cancer diagnosis and treatment, supported by funding from the European Commission under Horizon Europe programs. The MEA region sees a variance in healthcare facilities and accessibility, with the Gulf countries maintaining high standards of care, whereas African countries often grapple with resource limitations. Global NGOs also have numerous initiatives to enhance cancer care in Africa. The Asia-Pacific region witnesses a rising incidence of cancer due to aging populations, particularly in Japan and China, combined with increasing awareness and improving healthcare infrastructures in countries including India. In Asia-Pacific, there is a growing demand for cost-effective treatments. Countries focus on manufacturing generic versions of expensive drugs, making treatments more accessible.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Bone Metastasis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing product demand due to the rising prevalence of cancer
      • Expanded utility and application in clinical settings
    • Market Restraints
      • High cost of treatments and limited reimbursement policies
    • Market Opportunities
      • Development of sophisticated therapies and innovative medications
      • Extending strategic alliances between pharmaceutical companies and research institutions
    • Market Challenges
      • Presence of counterfeit medications
  • Market Segmentation Analysis
    • Type: Burgeoning tendency of osteolytic bone metastasis occurrence seen in cases of breast cancer, lung cancer, and multiple myeloma
    • Indication: Increasing propensity of bone metastasis from prostate cancer
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bone Metastasis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bone Metastasis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Greenlights First Denosumab Biosimilars, Expanding Treatment Options for Bone-Related Disorders

The FDA has approved Wyost/Jubbonti (denosumab-body; GP2411), marking the introduction of the first biosimilars to Xgeva/Prolia (denosumab) in the United States. In 2023, these biosimilars, produced by Sandoz, are set to manage osteoporosis, and hypercalcemia prevent in patients with bone metastases from solid tumors. This approval, which closely follows a similar sanction in Canada, positions Wyost/Jubbonti as a pioneering option in the U.S. market, especially notable as no denosumab biosimilars have yet to be approved by the European Union. [Published On: 2024-03-05]

FDA ApprovesMedtronic PLC.'s Enhanced OsteoCool 2.0 System for Bone Tumor Ablation

Medtronic PLC. has received FDA approval for OsteoCool 2.0, an advanced version of its radiofrequency ablation system designed to treat bone tumors, including metastatic cancers and benign lesions like osteoid osteomas. This updated system features a doubling of probe capacity, enabling the use of four internally cooled probes. This improvement allows for the simultaneous treatment of two vertebrae or the creation of larger ablation zones in non-spinal regions. Such advancements facilitate more efficient and extensive treatment options for patients suffering from painful bone tumors often associated with primary cancers of the breast, prostate, or lungs. [Published On: 2024-03-04]

Strategic Acquisition by Telix Pharmaceuticals Limited to Enhance Bone Cancer Treatment Options with QSAM Biosciences, Inc.' Innovative Radiopharmaceutical Platform

Telix Pharmaceuticals Limited officially announced its acquisition of QSAM Biosciences, Inc., a U.S.-based firm focusing on radiopharmaceutical development for treating primary and metastatic bone cancer. Central to this acquisition is QSAM's leading investigational drug, Samarium-153-DOTMP (153Sm-DOTMP), a bone-targeting radiopharmaceutical designed for dual purposes: alleviating pain in bone metastases and treating osteosarcoma, including pediatric cases. This therapeutic candidate significantly advances existing treatments by offering a superior safety profile, enhanced delivery precision, and streamlined production processes. [Published On: 2024-02-08]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bone Metastasis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Bone Metastasis Market, highlighting leading vendors and their innovative profiles. These include A.S. Lifesciences, AdvaCare Pharma USA, Aetos Pharma Private Limited, Amgen Inc., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Beacon Pharmaceuticals PLC., Cipla Limited, Dr. Reddy's Laboratories Ltd., Encapsula NanoSciences LLC, Fresenius Kabi AG, Getwell Pharma India Private Limited, Global Calcium PVT LTD, GLS Pharma Pvt. Ltd., LEXICARE PHARMA PVT. LTD., Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Bone Metastasis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Medications
      • Bisphosphonates
      • Pain Relievers
    • Therapy
      • Chemotherapy
      • Radiation Therapy
      • Surgical Treatments
  • Type
    • Mixed Bone Metastasis
    • Osteoblastic Bone Metastasis
    • Osteolytic Bone Metastasis
  • End-User
    • Hospitals & Clinics
    • Research Institutions.
    • Specialty Cancer Treatment Centers
  • Indication
    • Breast Cancer
    • Lung Cancer
    • Prostate Cancer
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing product demand due to the rising prevalence of cancer
      • 5.1.1.2. Expanded utility and application in clinical settings
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatments and limited reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of sophisticated therapies and innovative medications
      • 5.1.3.2. Extending strategic alliances between pharmaceutical companies and research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of counterfeit medications
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning tendency of osteolytic bone metastasis occurrence seen in cases of breast cancer, lung cancer, and multiple myeloma
    • 5.2.2. Indication: Increasing propensity of bone metastasis from prostate cancer
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bone Metastasis Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
  • 6.3. Therapy

7. Bone Metastasis Market, by Type

  • 7.1. Introduction
  • 7.2. Mixed Bone Metastasis
  • 7.3. Osteoblastic Bone Metastasis
  • 7.4. Osteolytic Bone Metastasis

8. Bone Metastasis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Research Institutions.
  • 8.4. Specialty Cancer Treatment Centers

9. Bone Metastasis Market, by Indication

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Lung Cancer
  • 9.4. Prostate Cancer

10. Americas Bone Metastasis Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bone Metastasis Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bone Metastasis Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Greenlights First Denosumab Biosimilars, Expanding Treatment Options for Bone-Related Disorders
    • 13.3.2. FDA ApprovesMedtronic PLC.'s Enhanced OsteoCool 2.0 System for Bone Tumor Ablation
    • 13.3.3. Strategic Acquisition by Telix Pharmaceuticals Limited to Enhance Bone Cancer Treatment Options with QSAM Biosciences, Inc.' Innovative Radiopharmaceutical Platform
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BONE METASTASIS MARKET RESEARCH PROCESS
  • FIGURE 2. BONE METASTASIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BONE METASTASIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BONE METASTASIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BONE METASTASIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BONE METASTASIS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BONE METASTASIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BONE METASTASIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BONE METASTASIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BONE METASTASIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BONE METASTASIS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BONE METASTASIS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BONE METASTASIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BONE METASTASIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BONE METASTASIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BONE METASTASIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BONE METASTASIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BONE METASTASIS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BONE METASTASIS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BONE METASTASIS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BONE METASTASIS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BONE METASTASIS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BONE METASTASIS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BONE METASTASIS MARKET SIZE, BY PAIN RELIEVERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BONE METASTASIS MARKET SIZE, BY PAIN RELIEVERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BONE METASTASIS MARKET SIZE, BY THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BONE METASTASIS MARKET SIZE, BY THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BONE METASTASIS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BONE METASTASIS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BONE METASTASIS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BONE METASTASIS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BONE METASTASIS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BONE METASTASIS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BONE METASTASIS MARKET SIZE, BY MIXED BONE METASTASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BONE METASTASIS MARKET SIZE, BY MIXED BONE METASTASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BONE METASTASIS MARKET SIZE, BY OSTEOBLASTIC BONE METASTASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BONE METASTASIS MARKET SIZE, BY OSTEOBLASTIC BONE METASTASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BONE METASTASIS MARKET SIZE, BY OSTEOLYTIC BONE METASTASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BONE METASTASIS MARKET SIZE, BY OSTEOLYTIC BONE METASTASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BONE METASTASIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BONE METASTASIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BONE METASTASIS MARKET SIZE, BY RESEARCH INSTITUTIONS., BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BONE METASTASIS MARKET SIZE, BY RESEARCH INSTITUTIONS., BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BONE METASTASIS MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BONE METASTASIS MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BONE METASTASIS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BONE METASTASIS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BONE METASTASIS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BONE METASTASIS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BONE METASTASIS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BONE METASTASIS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS BONE METASTASIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS BONE METASTASIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BONE METASTASIS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES BONE METASTASIS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BONE METASTASIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. AUSTRALIA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. AUSTRALIA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 157. CHINA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 158. CHINA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 159. CHINA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. CHINA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. CHINA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. CHINA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. INDIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 168. INDIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 169. INDIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 170. INDIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 171. INDIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. INDIA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. INDIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. INDIA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. INDONESIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. INDONESIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. INDONESIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 180. INDONESIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 181. INDONESIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 182. INDONESIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 183. INDONESIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. INDONESIA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. INDONESIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. INDONESIA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. JAPAN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. JAPAN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. JAPAN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 192. JAPAN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 193. JAPAN BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 194. JAPAN BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 195. JAPAN BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. JAPAN BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. JAPAN BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. JAPAN BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. MALAYSIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. MALAYSIA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. MALAYSIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 204. MALAYSIA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 205. MALAYSIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 206. MALAYSIA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 207. MALAYSIA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. MALAYSIA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. MALAYSIA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. MALAYSIA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. PHILIPPINES BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 216. PHILIPPINES BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 218. PHILIPPINES BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. PHILIPPINES BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. PHILIPPINES BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. SINGAPORE BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. SINGAPORE BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. SINGAPORE BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 228. SINGAPORE BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 229. SINGAPORE BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 230. SINGAPORE BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 231. SINGAPORE BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. SINGAPORE BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. SINGAPORE BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. SINGAPORE BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 249. TAIWAN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. TAIWAN BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. TAIWAN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 252. TAIWAN BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 253. TAIWAN BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 254. TAIWAN BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 255. TAIWAN BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. TAIWAN BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. TAIWAN BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. TAIWAN BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWAN BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. TAIWAN BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. THAILAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. THAILAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. THAILAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 264. THAILAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 265. THAILAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 266. THAILAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 267. THAILAND BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. THAILAND BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. THAILAND BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. THAILAND BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. THAILAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. THAILAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. VIETNAM BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. VIETNAM BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. VIETNAM BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 276. VIETNAM BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 277. VIETNAM BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 278. VIETNAM BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 279. VIETNAM BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. VIETNAM BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. VIETNAM BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 282. VIETNAM BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 283. VIETNAM BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 284. VIETNAM BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BONE METASTASIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 299. DENMARK BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. DENMARK BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. DENMARK BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 302. DENMARK BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 303. DENMARK BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 304. DENMARK BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 305. DENMARK BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. DENMARK BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. DENMARK BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. DENMARK BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. DENMARK BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. DENMARK BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. EGYPT BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. EGYPT BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. EGYPT BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 314. EGYPT BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 315. EGYPT BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 316. EGYPT BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 317. EGYPT BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. EGYPT BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. EGYPT BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 320. EGYPT BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 321. EGYPT BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. EGYPT BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 323. FINLAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. FINLAND BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. FINLAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 326. FINLAND BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 327. FINLAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 328. FINLAND BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 329. FINLAND BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. FINLAND BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. FINLAND BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 332. FINLAND BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 333. FINLAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. FINLAND BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. FRANCE BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. FRANCE BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. FRANCE BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 338. FRANCE BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 339. FRANCE BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 340. FRANCE BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 341. FRANCE BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. FRANCE BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. FRANCE BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 344. FRANCE BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 345. FRANCE BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 346. FRANCE BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 347. GERMANY BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 348. GERMANY BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 349. GERMANY BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 350. GERMANY BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 351. GERMANY BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 352. GERMANY BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 353. GERMANY BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 354. GERMANY BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 355. GERMANY BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 356. GERMANY BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 357. GERMANY BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. GERMANY BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. ISRAEL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 360. ISRAEL BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 361. ISRAEL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 362. ISRAEL BONE METASTASIS MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 363. ISRAEL BONE METASTASIS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
  • TABLE 364. ISRAEL BONE METASTASIS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
  • TABLE 365. ISRAEL BONE METASTASIS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 366. ISRAEL BONE METASTASIS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 367. ISRAEL BONE METASTASIS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 368. ISRAEL BONE METASTASIS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 369. ISRAEL BONE METASTASIS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 370. ISRAEL BONE METASTASIS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 371. ITALY BONE METASTASIS MARKET SIZE, BY TREATMENT TYPE, 2018-